Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Mar 1;28(3):487-496.
doi: 10.1093/annonc/mdw673.

Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials

F Khosrow-Khavar  1 , K B Filion  1 , S Al-Qurashi  2 , N Torabi  3 , N Bouganim  4 , S Suissa  1 , L Azoulay  1
Affiliations
Meta-Analysis

Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials

F Khosrow-Khavar et al. Ann Oncol. .

Abstract

Background: Aromatase inhibitors (AIs) have been associated with cardiovascular disease in adjuvant randomized controlled trials (RCTs) comparing these drugs to tamoxifen. However, it is unclear whether this risk is real or due to cardioprotective effects of tamoxifen. To address this question, we conducted a systematic review and meta-analysis of all RCTs of AIs and tamoxifen in adjuvant and extended adjuvant setting.

Patients and methods: We searched PubMed, Embase (OVID), Cochrane CENTRAL, WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov from inception to June 2016 for all RCTs comparing cardiovascular and cerebrovascular safety of AIs to tamoxifen, AIs to placebo or no-treatment, or tamoxifen to placebo or no-treatment in the adjuvant or extended adjuvant setting. Relative risks (RRs) were pooled using DerSimonian and Laird random-effects models with analyses stratified by RCT design.

Results: A total of 19 RCTs were included in the meta-analysis (n = 62 345). In the adjuvant setting, AIs were associated with a 19% (RR: 1.19, 95% confidence interval [CI]: 1.07-1.34) increased risk of cardiovascular events compared with tamoxifen. AIs were not associated with an increased risk compared with placebo in the extended-adjuvant setting (RR: 1.01, 95% CI: 0.85-1.20). In the adjuvant setting, tamoxifen was associated with a 33% (RR: 0.67, 95% CI: 0.45-0.98) decreased risk compared with placebo or no-treatment. The results from extended adjuvant RCTs comparing tamoxifen to placebo were inconclusive but suggestive of a small protective effect (RR: 0.91, 95% CI: 0.77-1.07).

Conclusions: The increased risk of cardiovascular events with AIs relative to tamoxifen is likely the result of cardioprotective effects of the latter. This new evidence should be considered when assessing the benefits and risks of AIs in the treatment of breast cancer.

Keywords: anastrozole; aromatase inhibitors; breast cancer; exemestane; letrozole; tamoxifen.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
PRISMA flow diagram describing systematic search for RCTs of aromatase inhibitors and tamoxifen. RCTs, randomized controlled trials.
Figure 2.
Figure 2.
Forest plot of relative risks of cardiovascular events with AIs and tamoxifen by trial design. Pooled relative risks and confidence intervals were obtained using DerSimonian and Laird random-effects models. AIs, aromatase inhibitors.
Figure 3.
Figure 3.
Forest plot of relative risks of cerebrovascular events with AIs and tamoxifen by trial design. Pooled relative risks and confidence intervals were obtained using DerSimonian and Laird random-effects models. AIs: aromatase inhibitors.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kelly E, Lu CY, Albertini S, Vitry A.. Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison. J Clin Pharm Ther 2015; 40: 76–82. - PubMed
    1. Early Breast Cancer Trialists' Collaborative G, Dowsett M, Forbes JF. et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015; 386: 1341–1352. - PubMed
    1. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006; 7: 633–643. - PubMed
    1. Colleoni M, Giobbie-Hurder A, Regan MM. et al. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 2011; 29: 1117–1124. - PMC - PubMed
    1. Bliss JM, Kilburn LS, Coleman RE. et al. Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol 2012; 30: 709–717. - PubMed

MeSH terms